ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer

Maria Lee, Sang Wun Kim, Eun Ji Nam, Hanbyoul Cho, Jae-Hoon Kim, YoungTae Kim, Sunghoon Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status.

Materials and Methods: One hundred specimens were collected during primary or secondary debulking from 67 patients with primary ovarian cancer, 24 patients with recurrent ovarian cancer, 5 patients with primary peritoneal cancer, and 4 patients with recurrent peritoneal cancer; samples were collected between August 2006 and June 2009. Tumor cells were isolated and cultured for 48 hours in media containing chemotherapy. The chemosensitivity index (CI) was calculated as 300 minus the sum of the cell death rate at 0.2×, 1×, and 5× drug concentrations, and the CI values were compared.

Results: CI values were obtained from 93 of 100 patients. The most active agents against primary disease were ifosfamide and paclitaxel. For primary serous adenocarcinoma, paclitaxel and irinotecan were the most active, followed by ifosfamide. For clear cell carcinoma, ifosfamide was the most active, followed by paclitaxel and irinotecan. Although not statistically significant, the CIs of cisplatin, carboplatin, paclitaxel, and docetaxel decreased as tumor grade increased. In 14 cases of recurrent disease, paclitaxel was the most active, followed by ifosfamide and cisplatin.

Conclusion: Ifosfamide and paclitaxel were the most active drugs for primary and recurrent disease. Therefore, we recommend further clinical studies to confirm the efficacy of paclitaxel, ifosfamide, and cisplatin combination chemotherapy for recurrent and primary ovarian cancer.

Original languageEnglish
Pages (from-to)1664-1671
Number of pages8
JournalYonsei medical journal
Volume55
Issue number6
DOIs
Publication statusPublished - 2014 Nov 1

Fingerprint

Ifosfamide
Ovarian Neoplasms
Paclitaxel
irinotecan
Adenosine Triphosphate
Drug Therapy
Neoplasms
docetaxel
Carboplatin
Combination Drug Therapy
Pharmaceutical Preparations
Cisplatin
Histology
Adenocarcinoma
Cell Death
Carcinoma
Mortality

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Maria ; Kim, Sang Wun ; Nam, Eun Ji ; Cho, Hanbyoul ; Kim, Jae-Hoon ; Kim, YoungTae ; Kim, Sunghoon. / ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer. In: Yonsei medical journal. 2014 ; Vol. 55, No. 6. pp. 1664-1671.
@article{2654fd90668e40e1aa52b32392d90187,
title = "ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer",
abstract = "Purpose: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status.Materials and Methods: One hundred specimens were collected during primary or secondary debulking from 67 patients with primary ovarian cancer, 24 patients with recurrent ovarian cancer, 5 patients with primary peritoneal cancer, and 4 patients with recurrent peritoneal cancer; samples were collected between August 2006 and June 2009. Tumor cells were isolated and cultured for 48 hours in media containing chemotherapy. The chemosensitivity index (CI) was calculated as 300 minus the sum of the cell death rate at 0.2×, 1×, and 5× drug concentrations, and the CI values were compared.Results: CI values were obtained from 93 of 100 patients. The most active agents against primary disease were ifosfamide and paclitaxel. For primary serous adenocarcinoma, paclitaxel and irinotecan were the most active, followed by ifosfamide. For clear cell carcinoma, ifosfamide was the most active, followed by paclitaxel and irinotecan. Although not statistically significant, the CIs of cisplatin, carboplatin, paclitaxel, and docetaxel decreased as tumor grade increased. In 14 cases of recurrent disease, paclitaxel was the most active, followed by ifosfamide and cisplatin.Conclusion: Ifosfamide and paclitaxel were the most active drugs for primary and recurrent disease. Therefore, we recommend further clinical studies to confirm the efficacy of paclitaxel, ifosfamide, and cisplatin combination chemotherapy for recurrent and primary ovarian cancer.",
author = "Maria Lee and Kim, {Sang Wun} and Nam, {Eun Ji} and Hanbyoul Cho and Jae-Hoon Kim and YoungTae Kim and Sunghoon Kim",
year = "2014",
month = "11",
day = "1",
doi = "10.3349/ymj.2014.55.6.1664",
language = "English",
volume = "55",
pages = "1664--1671",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer. / Lee, Maria; Kim, Sang Wun; Nam, Eun Ji; Cho, Hanbyoul; Kim, Jae-Hoon; Kim, YoungTae; Kim, Sunghoon.

In: Yonsei medical journal, Vol. 55, No. 6, 01.11.2014, p. 1664-1671.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer

AU - Lee, Maria

AU - Kim, Sang Wun

AU - Nam, Eun Ji

AU - Cho, Hanbyoul

AU - Kim, Jae-Hoon

AU - Kim, YoungTae

AU - Kim, Sunghoon

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Purpose: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status.Materials and Methods: One hundred specimens were collected during primary or secondary debulking from 67 patients with primary ovarian cancer, 24 patients with recurrent ovarian cancer, 5 patients with primary peritoneal cancer, and 4 patients with recurrent peritoneal cancer; samples were collected between August 2006 and June 2009. Tumor cells were isolated and cultured for 48 hours in media containing chemotherapy. The chemosensitivity index (CI) was calculated as 300 minus the sum of the cell death rate at 0.2×, 1×, and 5× drug concentrations, and the CI values were compared.Results: CI values were obtained from 93 of 100 patients. The most active agents against primary disease were ifosfamide and paclitaxel. For primary serous adenocarcinoma, paclitaxel and irinotecan were the most active, followed by ifosfamide. For clear cell carcinoma, ifosfamide was the most active, followed by paclitaxel and irinotecan. Although not statistically significant, the CIs of cisplatin, carboplatin, paclitaxel, and docetaxel decreased as tumor grade increased. In 14 cases of recurrent disease, paclitaxel was the most active, followed by ifosfamide and cisplatin.Conclusion: Ifosfamide and paclitaxel were the most active drugs for primary and recurrent disease. Therefore, we recommend further clinical studies to confirm the efficacy of paclitaxel, ifosfamide, and cisplatin combination chemotherapy for recurrent and primary ovarian cancer.

AB - Purpose: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status.Materials and Methods: One hundred specimens were collected during primary or secondary debulking from 67 patients with primary ovarian cancer, 24 patients with recurrent ovarian cancer, 5 patients with primary peritoneal cancer, and 4 patients with recurrent peritoneal cancer; samples were collected between August 2006 and June 2009. Tumor cells were isolated and cultured for 48 hours in media containing chemotherapy. The chemosensitivity index (CI) was calculated as 300 minus the sum of the cell death rate at 0.2×, 1×, and 5× drug concentrations, and the CI values were compared.Results: CI values were obtained from 93 of 100 patients. The most active agents against primary disease were ifosfamide and paclitaxel. For primary serous adenocarcinoma, paclitaxel and irinotecan were the most active, followed by ifosfamide. For clear cell carcinoma, ifosfamide was the most active, followed by paclitaxel and irinotecan. Although not statistically significant, the CIs of cisplatin, carboplatin, paclitaxel, and docetaxel decreased as tumor grade increased. In 14 cases of recurrent disease, paclitaxel was the most active, followed by ifosfamide and cisplatin.Conclusion: Ifosfamide and paclitaxel were the most active drugs for primary and recurrent disease. Therefore, we recommend further clinical studies to confirm the efficacy of paclitaxel, ifosfamide, and cisplatin combination chemotherapy for recurrent and primary ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84908244798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908244798&partnerID=8YFLogxK

U2 - 10.3349/ymj.2014.55.6.1664

DO - 10.3349/ymj.2014.55.6.1664

M3 - Article

VL - 55

SP - 1664

EP - 1671

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -